22 COVID-19 vaccines enter clinical trials in China: health official
Share - WeChat

BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- Student dorm AC installations fast-tracked in Shandong
- Russian professor: SCO nations deliver more together
- Typhoon Danas makes landfall in Taiwan, leaving 2 dead and hundreds injured
- 3 dead, 2 missing after mountain collapse in Southwest China
- China strengthens elderly care safety with new emergency response plan
- Three dead, two missing after Sichuan landslide